957130-49-3

Basic information

• Product Name: (R)-5-aMino-1,3-dihydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one
• Synonyms: (R)-5-aMino-1,3-dihydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one;(R)-5-amino-1,3-dihydrospiro[indene-2,3-pyrrolo[2,3-b]pyridin]-2(1H)-one(WX145561)
• CAS NO: 957130-49-3
• Molecular Formula: C₁₅H₁₃N₃O
• Molecular Weight: 251.28322
• Mol File: 957130-49-3.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 512.0±50.0 °C(Predicted)
• Appearance: /
• Density: 1.40±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 11.91±0.20(Predicted)
• CAS DataBase Reference: (R)-5-aMino-1,3-dihydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-5-aMino-1,3-dihydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one(957130-49-3)
• EPA Substance Registry System: (R)-5-aMino-1,3-dihydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one(957130-49-3)

Safety Data

• Hazardous Substances Data: 957130-49-3(Hazardous Substances Data)

Usage

General Description

(R)-5-amino-1,3-dihydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one is a chemical compound with a complex, spirocyclic structure. It contains an indene ring fused to a pyrrolopyridine ring system, with a spiro center connecting the two. The compound also contains a primary amine group (-NH2) and a ketone (C=O) functional group. (R)-5-amino-1,3-dihydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one has potential pharmaceutical applications, as spirocyclic compounds are often used in drug design due to their diverse and unique structures. The presence of the amine and ketone functional groups also suggests potential reactivity and biological activity. Due to its complex structure and potential pharmaceutical applications, this compound could be of interest to researchers and chemists in the pharmaceutical industry.

Upstream product

• 1246733-24-3 methyl 1-(tert-butyl)-2-hydroxy-1H-pyrrolo[2,3-b]pyridine-3-carboxylate 
• 1260403-55-1 [2-(chloromethyl)-4-(dibenzylamino)phenyl]methanol hydro chloride 
• 1260403-57-3 (R)-1’-(tert-butyl)-5-(dibenzylamino)-1,3-dihydrospiro[indene-2,3’-pyrrolo[2,3-b]pyridin]-2’(1’H)-one 
• 1246647-79-9 C₁₃H₁₅N₂O₃^(1-)*K⁽¹⁺⁾ 
• 1321609-73-7 C₁₁H₁₃N₂O^(1-)*Li⁽¹⁺⁾ 
• 1260403-56-2 methyl tert-butyl(3-methylpyridin-2-yl)carbamate 
• 1235305-63-1 N-(tert-butyl)-3-methylpyridin-2-amine 
• 1260403-54-0 [4-(dibenzylamino)-2-(hydroxymethyl)phenyl]methanol 
• 1260403-53-9 dimethyl 4-(dibenzylamino)benzene-1,2-dicarboxylate 
• 3430-17-9 2-bromo-3-picoline 
• 610-22-0 dimethyl 4-nitrophthalate 
• 610-27-5 4-nitrophthalic acid 
• 51832-31-6 4-amino-phthalic acid dimethyl ester 
• 939374-42-2 (+)-5-amino-1'-{[2-(trimethylsilyl)ethoxy]methyl}-1,3-dihydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one 

Downstream Products

• 1059185-34-0 2-[5-(3,5-difluorophenyl)-3-ethyl-5-methyl-2,4-dioxoimidazolidin-1-yl]-N-[(2R)-2'-oxo-1,1',2',3-tetrahydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-5-yl]acetamide 
• 957118-49-9 [3H]-MK 3207 
• 1189569-40-1 (2R)-5-{(1E)-3-[(7R,9aR)-7-(3,5-difluorophenyl)-9-oxohexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]prop-1-en-1-yl}-1,3-dihydrospiro[indene-2,3 '-pyrrolo[2,3-b]pyridin]-2'(1'H)-one 5 
• 1189569-34-3 (2R)-5-{(1E)-3-[2-(3,5-difluorophenyl)-5-(fluoromethyl)-2,4,5-trimethyl-6-oxopiperazin-1-yl]prop-1-en-1-yl}-1,3-dihydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one 
• 1189569-37-6 (2R)-5-({2-[(8R)-8-(3,5-difluorophenyl)-8-methyl-10-oxo-6,9-diazaspiro[4,5]dec-9-yl]ethyl}sulfanyl)-1,3-dihydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one 
• 1189569-08-1 (2R)-5-{3-[(8R)-8-(3,5-difluorophenyl)-8-methyl-10-oxo-6,9-diazaspiro[4,5]dec-9-yl]prop-1-yn-1-yl}-1,3-dihydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one 
• 1189569-38-7 (2R)-5-({2-[(8R)-8-(3,5-difluorophenyl)-8-methyl-10-oxo-6,9-diazaspiro[4,5]dec-9-yl]ethyl}sulfinyl)-1,3-dihydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one 
• 1189569-41-2 (2S)-6-{(1E)-3-[(8R)-8-(3,5-difluorophenyl)-8-methyl-10-oxo-6,9-diazaspiro[4,5]dec-9-yl]prop-1-en-1-yl}-2'-oxo-1,1',2',3-tetrahydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridine]-5-carbonitrile 
• 1189570-37-3 (2R)-5-({2-[(8R)-8-(3-difluorophenyl)-8-methyl-10-oxo-6,9-diazaspiro[4,5]dec-9-yl]ethyl}sulfanyl)-1'-{[2-(trimethylsiryl)ethoxy]methyl}-1,3-dihydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one 

Relevant articles and documents

Discovery of a First-In-Class Small Molecule Antagonist against the Adrenomedullin-2 Receptor: Structure-Activity Relationships and Optimization

Class B G-protein-coupled receptors (GPCRs) remain an underexploited target for drug development. The calcitonin receptor (CTR) family is particularly challenging, as its receptors are heteromers comprising two distinct components: The calcitonin receptor-like receptor (CLR) or calcitonin receptor (CTR) together with one of three accessory proteins known as receptor activity-modifying proteins (RAMPs). CLR/RAMP1 forms a CGRP receptor, CLR/RAMP2 forms an adrenomedullin-1 (AM1) receptor, and CLR/RAMP3 forms an adrenomedullin-2 (AM2) receptor. The CTR/RAMP complexes form three distinct amylin receptors. While the selective blockade of AM2 receptors would be therapeutically valuable, inhibition of AM1 receptors would cause clinically unacceptable increased blood pressure. We report here a systematic study of structure-activity relationships that has led to the development of first-in-class AM2 receptor antagonists. These compounds exhibit therapeutically valuable properties with 1000-fold selectivity over the AM1 receptor. These results highlight the therapeutic potential of AM2 antagonists.

HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS

Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: wherein HET, R1, R2, R3, R4, R5, L, L1, X1, X2, X3 and q are as defined herein. The compounds are inhibitors of adrenomedullin receptor subtype 2 (AM2). Also disclosed are the compounds for use in the treatment of diseases modulated AM2, including proliferative diseases such as cancer; pharmaceutical compositions comprising the compounds; methods for preparing the compounds; and intermediates useful in the preparation of the compounds.

Piperidinone carboxamide indane CGRP receptor antagonists

The present invention is directed to piperidinone carboxamide indane derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.